Previous 10 | Next 10 |
Zynex (NASDAQ: ZYXI) board approved a $10M share buyback program. The program will commence April 12, 2022, and end April 11, 2023, or when the $10.0 million buyback limit is reached. Zynex CEO Thomas Sandgaard said, "We believe that the current market value of our shares does not accurately ...
Zynex (NASDAQ:ZYXI) has reported prelim Q1 revenues of $30.5M to $31.5M (consensus: $32.33M) and adj. EBITDA of $3M - $4M. The revenue estimate is ~26% higher than Q121 and adjusted EBITDA is estimated to increase ~900% Y/Y. The pain management division saw Q1 order growth of 3% Y/Y. March 20...
Zynex Reports Preliminary First Quarter 2022 Results and Provides Business Update PR Newswire ENGLEWOOD, Colo. , April 8, 2022 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sa...
One group stands out as an interesting and potentially dramatically undervalued area of the market in the wake of the pandemic and its historical footprint: Medical device stocks. The healthcare system has been forever changed by the pandemic, which accelerated several core healthcare industr...
Gainers: Sportradar Group AG (SRAD) +5%. Eargo, Inc. (EAR) +4%. Zynex, Inc. (ZYXI) +3%. IVERIC bio, Inc. (ISEE) +3%. Sono Group N.V. (SEV) +3%. Losers: Vir Biotechnology, Inc. (VIR) -8%. Jounce Therapeutics, Inc. (JNCE) -6%. Travelzoo (TZOO) -5%. Health Catalyst, Inc (HCAT) -4%...
Zynex Recognized as Fourth Largest Biotechnology/Bioscience Company in Colorado PR Newswire ENGLEWOOD, Colo. , March 23, 2022 /PRNewswire/ -- Zynex, Inc . ( Nasdaq: ZYXI ) an innovative medical technology company specializing in the manufacture and sa...
One positive spin we can put on the “great growth stock bear market of 2022” – which, let’s face it, is what we are dealing with so far this year – is the value being created for future portfolio returns. We have seen indiscriminate selling in many high-grow...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Zynex, Inc. (ZYXI) Q4 2021 Earnings Conference Call February 24, 2022, 04:15 PM ET Company Participants Thomas Sandgaard – Chairman, President and CEO Dan Moorhead - CFO Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Monitoring Division Conference Call Participant...
Zynex press release (NASDAQ:ZYXI): Q4 GAAP EPS of $0.23 beats by $0.04. Revenue of $40.37M (+57.7% Y/Y) misses by $0.95M. Q1 revenue to be in the range of $29M-$32M vs. consensus of $35.73M. FY2022 revenue is estimated in the range of $150M-$170M vs. consensus of $171.54M. For further detai...
News, Short Squeeze, Breakout and More Instantly...
Zynex Sets Second Quarter 2024 Earnings Call PR Newswire ENGLEWOOD, Colo. , July 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain manage...
Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces PR Newswire ENGLEWOOD, Colo. , July 11, 2024 /PRNewswire/ -- Zy...